ABO exon and intron analysis in individuals with the A\(_\text{weak}\)B phenotype reveals a novel O\(_1\text{v}\)-A\(_2\) hybrid allele that causes four missense mutations in the A transferase

Bahram Hosseini-Maaf\(^1\), Åsa Hellberg\(^1\), Maria J Rodrigues\(^2\), M Alan Chester*\(^1\) and Martin L Olsson\(^1\)

Address: \(^1\)Dept. of Transfusion Medicine, Institute of Laboratory Medicine, Lund University & Blood Centre, University Hospital, SE-221 85 Lund, Sweden and \(^2\)Centro Regional de Sangue de Lisboa/IPS, Lisboa, Portugal

Email: Bahram Hosseini-Maaf - bahram.hosseini_maaf@transfumed.lu.se; Åsa Hellberg - asa.hellberg@transfumed.lu.se; Maria J Rodrigues - mjrodrigues@crsl.ips.min-saude.pt; M Alan Chester* - alan.chester@transfumed.lu.se; Martin L Olsson - Martin_L.Olsson@transfumed.lu.se
* Corresponding author

Abstract

**Background:** Since the cloning in 1990 of cDNA corresponding to mRNA transcribed at the blood-group ABO locus, polymorphisms due to ethnic and/or phenotypic variations have been reported. Some subgroups have been explained at the molecular level, but unresolved samples are frequently encountered in the reference laboratory.

**Results:** ABO blood grouping discrepancies were investigated serologically and by ABO genotyping [duplex polymerase-chain-reaction (PCR) – restriction-fragment-length-polymorphism (RFLP) and PCR – allele-specific-primer (ASP) across intron 6] and DNA sequencing of the ABO gene and its proposed regulatory elements. Blood samples from five individuals living in Portugal, Switzerland, Sweden and the USA were analysed. These individuals were confirmed to be of Black ethnic origin and had the unusual A\(_{\text{weak}}\)B phenotype but appeared to have the A\(_2\)B genotype without previously reported mutations associated with weak A or B expression. Sequencing of this A allele (having 467C>T and 1061delC associated with the common A\(_2\) [A201] allele) revealed three mutations regularly encountered in the O\(_1\text{v}\) [O02] allele: 106C>T (Val36Phe), 188G>A (Arg63His), 220C>T (Pro74Ser) in exons 3, 4 and 5, respectively. The additional presence of 46G>A (A1a16Thr) was noted, whilst 189C>T that normally accompanies 188G>A in O\(_1\text{v}\) was missing, as were all O\(_1\text{v}\)-related mutations in exons 6 and 7 (261delG, 297A>G, 646T>A, 681G>A, 771C>T and 829G>A). On screening other samples, 46G>A was absent, but two new O alleles were found, a Jordanian O\(_1\) and an African O\(_1\text{v}\) allele having 188G>A but lacking 189C>T. Sequencing of introns 2, 3, 4 and 5 in common alleles (A\(_1\) [A101], A\(_2\) [B101], O\(_1\), O\(_1\text{v}\)and O\(_2\) [O03]) revealed 7, 12, 17 and 8 polymorphic positions, respectively, suggesting that alleles could be defined by intronic sequences. These polymorphic sites allowed definition of a breakpoint in intron 5 where the O\(_1\text{v}\)-related sequence was fused with A\(_2\) to form the new hybrid. Intron 6 has previously been sequenced. Four new mutations were detected in the hybrid allele and these were subsequently also found in intron 6 of A\(_2\) alleles in other Black African samples.

Published: 17 November 2003

Received: 05 September 2003

Accepted: 17 November 2003

This article is available from: http://www.biomedcentral.com/1471-2156/4/17

© 2003 Hosseini-Maaf et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article’s original URL.
Background
The ABO blood group system is the most clinically significant system in transfusion and transplantation medicine. The A and B genes are co-dominant, so individuals can be phenotyped as A, B, AB or O. A common dimorphism in some populations leads to the division of blood group A into A1 and A2, the latter showing weaker antigenicity. On occasion, A2 activity is weakened further when competition due to a co-dominant B gene occurs (A1B phenotype).

ABO allele nomenclature poses significant problems that are still under consideration by the International Society of Blood Transfusion (ISBT). In the absence of an officially agreed terminology, alleles are referred to here by their serological activity and an alternative allele name is given in square brackets.

The ABO gene contains seven exons and a 1062 base pair (bp) sequence codes for a glycosyltransferase, of which the A1 [A101] allele (usually described as the consensus allele) product adds a monosaccharide (N-acetyl-α-D-galactosamine) to a specific acceptor glycoconjugate. The B [B101] allele produces a similar protein, differing only in four amino acids, but these changes result in a modified enzyme specificity [2]. The same acceptor glycoconjugate is utilised, but the B-specific monosaccharide, α-D-galactose, is added (for a review, see [3]). The coding region of the A2 [A201] allele differs from A1 by a seemingly innocuous 467C>T (Pro156Leu) substitution and a 1061delG that causes a frame-shift and extends the reading frame by 64 nucleotides [4]. Many other mutations have been described [5] that weaken these activities and result in weak A or B subgroups. Totally inactivating mutations result in the blood group O phenotype, the most common of which is a deletion at nucleotide (nt.) 261 (261delG) in exon 6 that results in a frame-shift and premature termination of translation [2]. Two major alleles of this type exist. The first allele (O1 [O01]) differs from the consensus A [A101] allele in all seven exons by only this mutation. The second allele (O1v [O02]) [6,7] has nine further mutations spread across exons 3–7 in addition to 261delG and an additional 13 mutations have been found amongst the 1052 nucleotides in intron 6 [8,9].

Other alleles have been described that are predicted to lead to amino acid substitutions or frame-shifts [5], or alternative splicing [10,11] and a dimorphic enhancer region has been reported [12-14]. Several alleles at the ABO locus appear to arise by crossing over between two dissimilar alleles. First described in 1996 [15], a B allele was continued as an O1v allele from downstream of the middle of the last and largest exon (exon 7). The B-enzyme-determining mutations occur after the cross-over point and the O1v sequence after this point only differs from the consensus (A1) sequence by two point mutations, of which only one would lead to an amino acid change (Val277Met). This change presumably weakened the A enzyme activity, as the resulting phenotype was A2, albeit from a B-O1v hybrid allele [A204]. Other examples on the same theme include several A′ alleles based on the 5’-ends of A or B alleles in combination with the 3’-end of the O1v allele [9,16]. However, many of the hybrid alleles described so far are hybrids of O1 and O1v, have 261delG, and hence are O (i.e. inactive) alleles [17].

We describe here a new hybrid A allele having O1v-A2 allele characteristics in five individuals of AweakB phenotype from different parts of the world, but having a common ethnic background. This is the first allele described in which the effect on enzyme activity of the mutations in the O1v allele prior to exon 6 can be shown.

Results
Blood group serology
The five individuals from Portugal (origin: Guinea Bissau), Sweden (n = 2, origins: Senegal and Zimbabwe), Switzerland (origin: the Dominican Republic), and the USA were all Black and of African or Afro-American descent. On routine typing they were found to express the A antigen weakly on their red blood cells (RBC) whilst the B antigen was expressed normally. Fresh blood samples from all five subjects were subjected to an extended serological analysis at the referring transfusion centres. Three of the samples were analysed with a panel of commercially available polyclonal and monoclonal anti-A reagents (described previously in [18]) for further characterisation of the weak A phenotype. One monoclonal reagent (Seraclone) agglutinated the RBC almost completely (3+ reaction with few unagglutinated cells) but the other reagents gave mixed field reactions (macroscopic reading ranging from negative to 1+/2+). All reactions were also read microscopically and weak agglutination with mixed field was verified also in the reagents yielding macroscopically negative readings. Adsorption of red cells with anti-A and subsequent elution yielded an eluate containing anti-A (only performed in one case). Anti-A was present in serum from all subjects but one also had a weak anti-A reactive only after
incubation at 4 °C. Saliva testing was not performed due to lack of saliva samples and/or non-secretor status as judged by Lewis blood group phenotyping.

Blood samples from the parents of the Portuguese individual were also investigated. Whilst the father had the common B phenotype, the phenotype of the mother was Aweak but with a strength of reactions suggesting an intermediate form of A antigen expression, weaker than A2 but stronger than the one observed in the AweakB cases studied here.

**Blood group genotyping**

All samples were found on initial genotype screening [19] to have the A'B genotype and lacked the majority of previously reported mutations associated with weak A or B expression [16,20]. Further analysis by A2-specific PCR-ASP [18] established the presence of the 1061delC mutation [4] and B-specific PCR-ASP [16] indicated the presence of a normal B allele [21]. In addition, enhancer minisatellite PCR analysis indicated that four of these samples were homozygous for four 43 bp-repeats in the CBF-NF/ Y-binding domain approximately 4 kbp upstream from the translation start codon, as expected [13]. Interestingly, the individual originating from the Dominican Republic was heterozygous for one and four repeats, thus deviating from the rule [13].

A BstUI-based PCR-RFLP test [7] results in cleavage between 188C and 189G in exon 4 of all known alleles except O1v (and some minor variants of O1 and O1v [5]), which has two mutations at these positions (188G>A and 189C>T). The indication that these five individuals already genotyped as A'B were also heterozygous for an O1v allele-specific mutation led us to sequence exons 1–7 to investigate the reason for this anomaly.

Based on information obtained about the geographic and ethnic origin of the individuals with the anomalous A allele, we also performed genomic typing of the FY and RHD blood group loci according to published methods [22,23]. The silent FY allele (based on the FYb sequence with a disrupted GATA-1-binding motif in the promoter region [24]) commonly found in individuals of Black ethnic origin but not in Caucasians was detected in the homozygous or heterozygous state in all five cases whilst the RHD pseudogene [23] exclusively found in some Blacks was detected in the Portuguese sample only.

DNA was also isolated from blood from the parents of the Portuguese AweakB individual. The mother was genotyped as A2O1 and the father as BO1. Further investigation of the mother’s A2-like allele showed the same hybrid allele as her son and the other four index cases, as expected.

**ABO exon sequences**

The complete coding region (all seven exons, comprising 1128 bp) of the A2 allele was sequenced in all five samples.

The nucleotide sequence in exons 6 and 7 was identical to the non-Asian A1 consensus allele except for the characteristic mutations (467C>T and 1061delC in exon 7) found in the common A2 allele.

The sequences in exons 1–5 were similar to the consensus allele, except for 106G>T (exon 3), 188G>A (exon 4) and 220C>T (exon 5), all consistent with the presence of an O1v allele. Surprisingly, the O1v-specific mutation, 189C>T, was absent, whereas a hitherto undescribed mutation in exon 2 (46C>G) was found in all five samples. As opposed to the situation in O1v, the effect of these missense mutations can be seen in the translated trans- ferase, as the O1/O1v-specific 261delG mutation is not present in this allele. The amino acids predicted to occur as well as their relative locations in the translated protein are shown in Figure 1.

A possible hybrid allele breakpoint was suspected somewhere between the end of exon 5 and the beginning of exon 6. We therefore sequenced the intervening intron 5 (see below) in an attempt to localise the cross-over region.

None of the more than 100 samples screened by PCR-ASP (i.e. at least 200 alleles, comprising over 50 O1 and O1v alleles and at least 10 A1, A2, B, O2 and O hybrid alleles, as well as several weak A alleles) had the new mutation, 46C>G (Ala16Thr). Amongst all these samples one O1 allele from a Jordanian individual was found to have the O1v-characteristic 188G>A (Arg63His) mutation. One O1v allele from an African individual lacked the O1v-characteristic 189C>T (silent) mutation.

**ABO intron sequences**

*Intron 5*

Intron 5 from a number of individuals with the common alleles, A1 (two homozygotes), A2 (two homozygotes), B (one homozygote, one heterozygote), O1 (two homozygotes), O1v (two homozygotes), O2 [O03] (three heterozygotes) and the new suspected hybrid alleles was sequenced. Three A2 and three O1v alleles from Black African donors were also sequenced for comparison. Eight polymorphic nucleotide positions were found in the 554 bp sequence and these are shown in Table 1. Intron 5 sequences in the Black African samples were identical to the respective alleles of the other (Caucasian) control material. The sequence in the new allele was consistent with a crossover between an O1v and an A2 allele after nt. 103insCCC but before 306C in intron 5. This is shown schematically in Figure 2.
Introns 2, 3 and 4

Since the new allele has a novel mutation in exon 2 (46G>A) and an unexpected lack of the O1v-specific mutation in exon 4 (189C>T), other introns in the A2-like allele of the five AweakB samples were also sequenced and all gave identical results. Samples from the same 13 Caucasian and three Black individuals examined for intron 5 above were also analysed (Table 1). Intron 1 was not examined due to its size (approx. 13,000 bp). We found 7, 12 and 17 polymorphic sites (point mutations, deletions and insertions) in introns 2, 3 and 4, respectively, in the common alleles (Table 1).

The intron 2–4 sequences of the novel allele were identical to the O1v alleles sequenced except for three adjacent mutations in intron 3. The first, 2051T>C, caused a reversion to the consensus from O1v-specific, whereas 354G>A and 399G>A were mutations not previously encountered in any allele. Intron 3 in the O1v alleles from the control...
The donors of African origin were sequenced and the sequence was identical to Caucasian $O^{1v}$ alleles.

### Table 1: Polymorphic nucleotide positions in introns 2–5 of the ABO gene.

#### Intron 2 (724 bp) nt. position

| dbSNP rs | 20738 | 20738 | 68728 | 687621 | 20738 |
|----------|-------|-------|-------|--------|-------|
| $A^1$    | A     | C     | C     | T      | C     |
| $A^2$    | A     | C     | C     | T      | C     |
| $B$      | A     | C     | C     | T      | C     |
| $O^1$    | A     | C     | T     | G      | C     |
| $O^{1v}$ | A     | C     | C     | T      | C     |
| new      | A     | C     | C     | T      | C     |

#### Intron 3 (1451 bp) nt. position

| dbSNP rs | 81767 | 57962 | 57948 | 8176702 | 57525 | 57434 |
|----------|-------|-------|-------|---------|-------|-------|
| $A^1$    | C     | G     | G     | A      | C     |
| $A^2$    | C     | G     | G     | A      | A     |
| $B$      | C     | G     | C     | A      | T     |
| $O^1$    | C     | G     | G     | A      | C     |
| $O^{1v}$ | T     | G     | T     | C      | G     |
| new      | A     | A     | T     | C      | C     |

#### Intron 4 (1686 bp) nt. position

| dbSNP rs | 784814 | 615120 | 81767 | 62559 | 8176708 | 547495 | 62603 | 62679 | 63875 | 51741 | 51470 | 64194 | 64195 | 81767 | 4962 |
|----------|--------|--------|-------|-------|---------|--------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| $A^1$    | G      | C      | C      | G      | A      | A      | T      | C      | T      | C      | G      | T      | T      |
| $A^2$    | G      | C      | C      | A      | A      | T      | C      | T      | C      | G      | T      | G      |
| $B$      | G      | C      | C      | G      | A      | T      | T      | C      | C      | G      | T      | C      |
| $O^1$    | G      | C      | C      | G      | A      | T      | T      | T      | C      | A      | G      | G      | T      |
| $O^{1v}$ | C      | T      | A      | G      | C      | G      | C      | C      | A      | G      | G      | C      |
| new      | C      | T      | A      | G      | C      | G      | C      | T      | A      | G      | G      | C      |

#### Intron 5 (554 bp) nt. position

| dbSNP rs | 817671 | 81767 | 81767 | 8176717 | 81767 |
|----------|--------|-------|-------|---------|-------|
| $A^1$    | T      | C      | G      | C      | G      |
| $A^2$    | T      | C      | G      | C      | G      |
| $B$      | T      | C      | G      | C      | G      |
| $O^1$    | C      | CCCC   | A      | C      | G      |
| $O^{1v}$ | T      | CCCC   | G      | A      | A      |
| new      | T      | CCCC   | G      | C      | G      |

* C/T etc. indicates dimorphism at this position in the same allele from different individuals. ** Insertion of GTGTGGACAGAAG between nt. 72C and 73C of the consensus ($A^1$ [A101]) sequence in intron 4. Deviations from the consensus sequence are highlighted (bold italics).
Allele-specific variations in intron 6 have already been described [8,9]. Four new mutations were found in the new hybrid allele when compared to the A consensus sequence (277A>G, 286C>T, 911G>T and 952A>G). However, intron 6 in three normal A² alleles from Black Africans with the common A² phenotype also had these mutations.

Discussion
Detailed analysis of the alleles at the blood group ABO locus is shedding light on the effect of polymorphism in different regions of the translated products, the blood group A and B glycosyltransferases, and ultimately the clinically important ABO phenotype of red cells. Factors with the potential to influence the glycosyltransferase activities include base insertions, deletions and substitutions mainly in exons 6 and 7 (for review see [5,25]), hybrid alleles [17], splice-site mutations [10,11], variations in enhancer activity [12-14], promoter methylation [26], promoter mutations [27] and alternative promoter regions [28].

The new allele described here is unusual in several respects. The O¹v-characteristic mutations, 106C>T, 188G>A and 220C>T in exons 3, 4 and 5, respectively, in combination with the common A²-specific sequence in exon 7 suggested that the allele is an O¹v-A² [002-A201] hybrid having a crossing-over point after nt. 220 in exon 5 and before nt. 261 in exon 6. A deletion at nt. 261 is the most common inactivating event creating O alleles and is present in both O¹ and O¹v alleles and hybrid variants of these as shown in Figure 3. This mutation is absent from the five hybrid alleles described here and hence the cross-over should occur upstream of this position. In an attempt to determine the cross-over point more precisely and confirm the identity of the two contributing alleles we sequenced the intervening intron (intron 5) in the hope that allele-specific mutations were present in this intron, by analogy with our previous findings in intron 6 [9]. As Table 1 shows, eight of the 554 nucleotides in the intron were polymorphic. In this intron the A¹, A², B and O¹ alleles are very similar, differing only at nt. 336 in the O¹ allele and at nt. 529 in only one of the three B alleles tested. More pronounced differences were observed in the O² alleles that differed at each of the first three polymorphic positions (the complex variations in the O² allele will be presented elsewhere), and in the O¹v alleles, that differed at four of these sites. This latter information allowed us to determine the crossing-over point to occur in intron 5 between nt. 103 and 306, and that the allele is indeed an O¹v-A² hybrid (Figure 2).

This new allele showed some additional interesting characteristics. The mutation, nt. 46C>G (Ala16Thr) in exon 2, has not been described in any other context, nor could we detect this mutation when we analysed 260 alleles from individuals of diverse ethnic background (of whom about 40 were African). Its occurrence in all five index samples, albeit from individuals of Black African descent, collected from diverse parts of the world is surprising.

Few mutations have been found in exon 4. Both 188G>A and 189C>T have hitherto been exclusive characteristics of the O¹v allele; 190 G>A has only been found in some Brazilian Black O¹ alleles [29]; and 203G>C occurred in some Scandinavian Aweak alleles [16]. The finding of 188G>A without 189C>T in the new allele was also unexpected. When we screened more than 200 alleles at these positions we found one otherwise normal O¹v allele (African) having 188G>A but lacking 189C>T and one otherwise normal O¹ allele (Jordanian) having 188G>A. Although infrequent, additional genetic diversity obviously exists in individuals with common ABO phenotypes.

Several hybrid alleles at the ABO locus have been reported previously (reviewed in [17] and summarised in Figure 3). About half of these alleles are O alleles containing the common inactivating deletion at nt. 261 contributed by
Figure 3
Known hybrid alleles at the ABO locus. The common alleles are also shown for comparison. Only changes from the consensus (A1-1) sequence are shown. Mutations causing amino acid changes are shown in bold face. The yellow areas indicate a reading frame shift. The blue areas indicate untranslated regions. The introns are represented by the thick, dark vertical bars. The blue rectangles indicate the region of the allele where a crossing over event occurred. ?, indicates that the nucleotide at this position was not described.

| Exon | 1 | 2 | 3 | 4 | 5 | 6 | 7 | Reference |
|------|---|---|---|---|---|---|---|-----------|
| nt in position | 261 | 106 | 130 | 132 | 241 | 297 | 132 |          |
| A allele | A104 | A102 | A101 | A100 | A99 | A98 | A97 |          |
| T | G | G | C | G | G | G | A |          |
| C | T | C | T | C | C | C | A |          |
| G | A | T | A | A | A | A | A |          |
| O1 allele | O104 | O102 | O101 | O100 | O99 | O98 | O97 |          |
| T | G | G | C | G | G | G | A |          |
| C | T | C | T | C | C | C | A |          |
| G | A | T | A | A | A | A | A |          |
| O2 allele | O204 | O202 | O201 | O200 | O199 | O198 | O197 |          |
| T | G | G | C | G | G | G | A |          |
| C | T | C | T | C | C | C | A |          |
| G | A | T | A | A | A | A | A |          |

| Known hybrid alleles | A104 | A102 | A101 | A100 | A99 | A98 | A97 | Reference |
|----------------------|------|------|------|------|------|------|------|-----------|
| T | G | G | C | G | G | G | A |          |
| C | T | C | T | C | C | C | A |          |
| G | A | T | A | A | A | A | A |          |
| O1v allele | O1v04 | O1v02 | O1v01 | O1v00 | O1v99 | O1v98 | O1v97 |          |
| T | G | G | C | G | G | G | A |          |
| C | T | C | T | C | C | C | A |          |
| G | A | T | A | A | A | A | A |          |

The mutations found early on in intron 3 of this new hybrid allele (the consensus 205C rather than the O1v-specific 205C>T, as well as the unique 354G>A and 399G>A)
appear to be a specific characteristic of this new allele since intron 3 of the three control O1r alleles from Black African individuals did not differ from Caucasian samples. On the other hand, the four new mutations found in intron 6 of the new hybrid allele were also found in the three Black African A2 alleles, which led us to conclude that the alterations observed in intron 6 may simply reflect a common ancestral A2 allele of African evolutionary lineage.

The A and B glycosyltransferases compete for the same acceptor glycoconjugates. However, the weaker A activity due to this new allele was also observed serologically, although to a lesser degree, in the mother of one of these AweakB individuals who had inherited the hybrid allele in combination with an O allele and hence lacked a B gene. This may indeed be the reason why all five index samples studied here were AweakB. Obviously, the weakening effect of this hybrid is relatively mild so that the Aweak phenotype, produced when the A hybrid glycosyltransferase is allowed to convert the available acceptor glycoconjugates to A without any competition from a B transferase, will sometimes escape detection in routine laboratories, especially if automated blood grouping equipment is used.

Conclusions
A new hybrid, Aweak allele with O1v and A2 characteristics with a crossing over point in intron 5 has been found at the blood group ABO locus in five individuals of diverse Black African backgrounds. To our knowledge this is the only defined ABO subgroup allele so far associated with an African ethnic origin.

Sequencing of all seven exons of these Aweak alleles showed two major exons (exons 6 and 7) that were identical to the most frequent A2 allele, although the intervening intron 6 had mutations only found so far in Black Africans. Exons 1–5 had sequences consistent with the O1v allele, except for two novel changes, the most important one of which (46G>A) results in an amino acid substitution in the putative trans-membrane region of the translated protein (glycosyltransferase). The other novel change (lack of 189C>T) led further to the identification of two new O alleles.

This new hybrid allele shows how mutations in early exons, far from the enzyme product’s active site, can affect expression of the blood group A antigen on the erythrocyte surface.

Methods
Blood samples and blood group serology
Blood samples from individuals living in Portugal, Sweden, Switzerland and the USA were referred to our laboratory for genomic analysis due to unclear phenotyping.

Blood samples from first-degree relatives were only obtained in one case.

One hundred and thirty blood samples available at the Blood Centre, University Hospital, Lund from blood donors and other apparently healthy individuals with mixed phenotypes and mixed ethnicity (Africans, Europeans, Jordanians) were used for screening purposes. Their ABO group was determined according to current practice [30].

Routine ABO genotyping
All oligonucleotide primers used were synthesized by DNA Technology ApS (Aarhus, Denmark). DNA was prepared in Lund using a simple salting-out method [31].

The initial ABO genotyping comprised duplex PCR-RFLP and PCR-ASP analysis of exons 6 and 7 across intron 6 and subsequently DNA sequencing of the ABO gene and its regulatory elements was performed [7,16,19,20].

Selected homozygous and heterozygous DNA (samples homozygous for O2 and B allele were not available) from blood donors and other apparently healthy individuals at the reference laboratory in Lund was used for identification of introns 2 to 5 from the common alleles A1, A2, B, O1, O1r and O2.

PCR amplification of the ABO gene for DNA sequencing
Primers used to amplify DNA fragments and for allele-specific direct sequencing of the seven exons and intron 6 are described elsewhere [16].

Alternatively, polymerase chain reaction (PCR) was carried out using Expand High Fidelity PCR system (Roche Molecular Systems, Pleasanton, CA, USA) to amplify different intron fragments and for screening for mutations 188G>A and 46A>G. Amplifications were performed with primer pairs as shown in Table 2. An internal positive control primer pair was used in each PCR reaction. Amplification was performed in a reaction volume of 20 µL with 0.5 µmol/L of each primer, 2 nmol of each dNTP, and 100 ng of genomic DNA. As thermostable enzyme we used 0.5U from the Expand High Fidelity PCR System in the supplied buffer 2 with a final Mg2+ concentration of 1.5 mM according to the manufacturer (Roche Molecular Systems). After an initial denaturation step at 95°C for 2 min followed 10 cycles of denaturation (94°C for 20 s), annealing (65°C for 45 s) and extension (72°C for 1.5 min), then 25 cycles at 94°C for 20 s, 61°C for 30 s and 72°C for 1 min and a final extension for 5 min.

PCR products were excised from 3% agarose gels (Seakem, FMC Bioproducts, Rockland, ME, USA) stained with ethidium bromide (0.56 mg/l gel, Sigma Chemicals, St.
Louis, MO, USA) following high-voltage electrophoresis and purified using the Qiaquick gel extraction kit (Qiagen GmbH, Hilden, Germany).

The Big Dye Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA) and an ABI PRISM 310 Genetic Analyser (Applied Biosystems) were used for direct DNA sequencing with capillary electrophoresis and automated fluorescence-based detection according to the manufacturer’s instructions. Sequence analysis was performed with SeqEd software 1.03 (Applied Biosystems).

### Authors’ Contributions

Authors BHM and ÅH performed the molecular biology experimentation including PCR and DNA sequencing. Author MJR collected blood samples and performed serological blood group studies. Authors BHM, AC and MLO conceived and coordinated the study and drafted the manuscript. All authors read and approved the submitted manuscript.

### Table 2: Oligonucleotide primers used for PCR amplification, sequencing and screening in this study.

| Primer name | F/R | Nucleotide sequence (5′ → 3′) | Position | Function |
|-------------|-----|-------------------------------|----------|----------|
| mo-21s      | F1-3| GGTGAGAGAAGGAGGTTGAG          | intron 1 | amplification-sequencing of intron 2 for all alleles |
| mo-31r      | R1-4| CCAAGCACCCCCGCCAGCAA          | intron 3 | amplification-sequencing of intron 2 or screening of 46G>A |
| ABO-46A-F   | F4  | CCAGGAAACACAAATCAGCAA         | exon 2   | screening of 46G>A |
| ABO-106G-R  | R3  | TAGACCTTCTGGGCTTAGGAC         | exon 3   | amplification of O2 allele in intron 2 |
| ABO-106T-R  | R3  | AGACCTTCTGGGCTTAGGAC         | exon 3   | amplification of new hybrid allele in intron 2 |
| ABO-inl-123F| F   | GTTGAGAGAAGGAGGTTGAG          | intron 2 | sequencing of intron 2 |
| ABO-inl-660R| R   | CTCAGGATGGTCTCTTCCTTCC       | intron 2 | sequencing of intron 2 |
| ABO-133s    | R5  | GGCAGAGAATCGAGTACCTGAGG      | exon 3   | amplification-sequencing of introns 3 and 4 |
| ABO-202 cons-R|R3  | GGGAGGCACTGACATTATACC        | intron 4/exon 4 | amplification-sequencing of hybrid allele in intron 3 and screening |
| ABO-188A-R  | R6  | ATACCTTGGCAAGAGACGT          | intron 4/exon 4 | amplification-sequencing of hybrid allele in intron 3 and screening |
| ABO-220 T-R | R7-10| CCACGTTGTCAGCAGCTTTTAAG      | exon 5   | amplification-sequencing of O2 allele in introns 3 and 4 |
| ABO-220 C-R | R8-11| CACGTTGTCAGCAGCTTTTAAG       | exon 5   | amplification-sequencing of B allele in introns 3 and 4 |
| ABO-inl-F   | R9  | GGTGAGAGAAGGAGGTTGAG          | intron 3 | screening of 188G>A mutation in exon 4 |
| ABO-inl-425F| F  | GGTGAGAGAAGGAGGTTGAG          | intron 3 | sequencing of intron 3 |
| ABO-inl-672F| F  | GTTGAGAGAAGGAGGTTGAG          | intron 3 | sequencing of intron 3 |
| ABO-inl-916F| F  | CTCAGGATGGTCTCTTCCTTCC       | intron 3 | sequencing of intron 3 |
| mo-41s      | R10-11| TAAATCTTGGCTCTAGTACTAAC       | intron 3 | amplification-sequencing of intron 4 |
| ABO-inl-170F| F  | GACCTTGGCCCTGTCTTCTTCA        | intron 4 | sequencing of intron 4 |
| ABO-inl-429R| R  | GACTTGGCCCTGTCTTCTTCA        | intron 4 | sequencing of intron 4 |
| ABO-inl-852F| R  | TAGAAGGCTTCTGTCTGGAG          | intron 4 | sequencing of intron 4 |
| ABO-inl-877R| R  | GTTGAGAGAAGGAGGTTGAG          | intron 4 | sequencing of intron 4 |
| ABO-inl-1122F| F | CTCAGGATGGTCTCTTCAATCTCTC   | intron 4 | sequencing of intron 4 |
| ABO-inl-1411F| F | CTCAGGATGGTCTCTTCAATCTCTC   | intron 4 | sequencing of intron 4 |
| ABO-229F    | R12-13| CTACAGGATGGTCTCTTCAATCTCTC   | intron 4 | sequencing of intron 4 |
| ABO-297A-R  | R12 | GTTGAGAGAAGGAGGTTGAG          | exon 6   | amplification-sequencing of all alleles in intron 5 |
| ABO-297G-R  | R13 | GTTGAGAGAAGGAGGTTGAG          | exon 6   | amplification-sequencing of B, O1', and hybrid allele in intron 5 |
| mo-101s     | F1-3| GGTGAGAGAAGGAGGTTGAG          | intron 6 | internal control primer pair in screening |
| EPB-219R    | R1-4| CACGTTGTCAGCAGCTTTTAAG       | exon 7   | internal control primer pair in screening |

* Forward/reverse primer. ** O2, B and hybrid alleles were examined in heterozygous samples. The numeral superscripts denote primer combinations. Primers with the same number were used in the same primer mixes for amplification of ABO gene fragments.

### Note

1Nomenclature used in the Blood Group Antigen Gene Mutation Database [http://www.bioc.aecom.yu.edu/hgmut/abo.htm](http://www.bioc.aecom.yu.edu/hgmut/abo.htm).
Acknowledgements
Dr. P. Marinho, Clinica Medica Dr J. Chaves, and Dr. T. Chabert, Centro Regional de Sangue de Lisboa, Portugal, Dr. Viveka Stiller, Division of Clinical Immunology and Transfusion Medicine, Karolinska Hospital (present affiliation: Huddinge University Hospital), Stockholm, Sweden, Ms. Nicole Eicher, Blood Transfusion Service SRC, Bern, Switzerland and Ms. Marilyn Moulds, Immucor/Gamma Reference Laboratories, Atlanta, GA/Houston, TX, USA are thanked for referral of blood samples for genetic analysis after performing the initial serological investigation. We are also grateful to Dr. Geoff Daniels and Dr. Nidal Irshaid for providing samples of African and Jordanian blood donors, respectively. This work was supported financially by the Swedish Research Council (project no. K2002-71X-14251-01A), the Medical Faculty at Lund University/ALF, the Lund University Hospital Donation Funds, the Claes Hogman SAGMAN-stipendium.

Part of this work was presented at the 8th European Regional Congress of the International Society of Blood Transfusion held in Istanbul, Turkey on July 5-9 2003 and published in abstract form [1].

References
1. Hosseini-Mafa B, Hellberg A, Eicher N, Rodrigues MJ, Chester MA, Olsson ML: A novel O 1 -A hybrid allele at the ABO blood group locus is associated with the A B Phenotype [abstract]. Proceedings (Abstract Book) of the 8th Congress of the International Society of Blood Transfusion 2003, 120:P341.
2. Yamamoto F, Clauser H, White T, Marken J, Hakomori S: Molecular genetic basis of the histo-blood group ABO system. Nature 1990, 345:229-233.
3. Watkins WM: Biochemistry and genetics of the ABO, Lewis and P blood group systems. In Advances in Human Genetics Edited by: Harris H, Heschtam K. New York: Plenum Press; 1980:1-136.
4. Yamamoto F, McNeill PD, Hakomori S: Human histo-blood group A 2 -transfere coded by A 2 allele, one of the A subtypes, is characterized by a single base deletion in the coding sequence, which results in an additional domain at the carboxyl terminal. Biochem Biophys Res Commun 1992, 187:366-374.
5. Chester MA, Olsson ML: The ABO blood group gene – A locus of considerable genetic diversity. Transfus Med Rev 2001, 15:295-313.
6. Yamamoto F, McNeill PD, Yamamoto M, Hakomori S, Harris T: Molecular genetic analysis of the ABO blood group system: A A 1 and B A 1 alleles. Vox Sang 1993, 64:171-174.
7. Olsson ML, Chester MA: Frequency occurrence of a variant O 1 gene at the blood group ABO locus. Vox Sang 1996, 70:26-30.
8. Suzuki K, Iwata M, Tsuji H, Takagi T, Tamura A, Ishimoto G et al.: A de novo recombination in the ABO blood group gene and evidence of recombination products. Hum Genet 1997, 99:454-461.
9. Olsson ML, Chester MA: Heterogeneity of the blood group A allele: genetic recombination of common alleles can result in the A 1 , phenotype. Transfus Med 1998, 8:231-238.
10. Olsson ML, Irshaid NM, Kuosmanen N, Pirkola A, Chester MA: A splice-site mutation defines the Af sinn allele at the blood group ABO locus [abstract]. Transfusion 2000, 40(10S):905.
11. Yu LC, Twc YC, Chou ML, Chang CT, Wu CY, Lin M: Molecular genetic analysis for the B (3) allele. Blood 2002, 100:1490-1492.
12. Kominato Y, Tsuchiya H, Tsukita K, Takizawa H, Yamamoto F: Transcription of human ABO histo-blood group genes is dependent upon binding of transcription factor CBF/NF-Y to minisatellite sequence. J Biol Chem 1997, 272:25890-25896.
13. Chester MA, Olsson ML: Allele-related variation in minisatellite repeats involved in the transcription of the blood group ABO gene. Transfus Med 1999, 9:219-226.
14. Yu LC, Chang CY, Twc YC, Lin M: Human histo-blood group ABO glycosyltransferase genes: different enhancer structures with different transcriptional activities. Biochem Biophys Res Commun 2000, 273:459-466.
15. Ogasawara K, Yabe R, Uchikawa M, Saitou N, Bannai M, Nakata K et al.: Molecular genetic analysis of variant phenotypes of the ABO blood group system. Blood 1996, 88:2732-2737.
16. Olsson ML, Irshaid NM, Hosseini-Mafa B, Hellberg A, Moulds MK, Sareneva H et al.: Genomic analysis of clinical samples with serologic ABO blood group discrepancies: identification of 15 novel A and B subgroup alleles. Blood 2001, 98:1585-1593.
17. Olsson ML, Chester MA: Polymorphisms and recombination events at the ABO locus: a major challenge for genomic ABO blood grouping strategies. Transfus Med 2001, 11:295-313.
18. Olsson ML, Chester MA: Polymorphisms at the ABO locus in subgroup A individuals. Transfusion 1996, 36:309-313.
19. Olsson ML, Chester MA: A rapid and simple ABO genotype screening method using a novel B/O versus A/O discriminating nucleotide substitution at the ABO locus. Vox Sang 1995, 69:242-247.
20. Olsson ML, Hosseini-Mafa B, Hellberg Å, Chester MA: Allele-specific primer PCR across exon 6 resolves potential genotyping errors caused by recombiant hybrid alleles at the ABO locus [abstract]. Transfusion 1998, 38(10S):35.
21. Yamamoto F, Hakomori S: Sugar-nucleotide donor specificity of histo-blood group A and B transfersases is based on amino substitution. J Biochem 1990, 108:1925-1926.
22. Olsson ML, Hansson C, Avent ND, Akesson IE, Green CA, Daniels GL: A clinically applicable method for determining the three major alleles at the Duffy (FY) blood group locus using polymerase chain reaction with allele-specific primers. Transfusion 1998, 38:168-173.
23. Singleton BK, Yamaoto T, Matsumoto K, Yasui K, Tsukita J et al.: Alternative primer pairs for detecting the Duffy (FY) blood group phenotype. Transfusion 1999, 39:39-46.
24. Kominato Y, Yamaoto T, Matsumoto K, Yasui K, Tsukita J et al.: Characterization of the human ABO gene promoter in erythroid cell lineages. J Biol Chem 2002, 277:37936-37948.
25. Olsson ML: The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in Africans with the RH D-negative blood group phenotype. Blood 2000, 95:1-18.
26. Vengelen-Tyler V: American Association of Blood Banks; 1999.
27. Singleton BK, Yamaoto T, Matsumoto K, Yasui K, Tsukita J et al.: Characterization of the human ABO gene promoter in erythroid cell lineages. J Biol Chem 2002, 277:37936-37948.
28. Olsson ML: Molecular analysis of the O allele at the blood group ABO locus in populations of different ethnic origin reveals novel crossing-over events and point mutations. Biochem Biophys Res Commun 1997, 234:779-782.
29. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
30. Patenaude SI, Seto NO, Borisova SN, Azapenko A, Marcus SL, Palic M et al.: The structural basis for specificity in human ABO(H) blood group biosynthesis. Nat Struct Biol 2002, 9:685-690.
31. Guex N, Peitsch MC: SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997, 18:2714-2717.
32. Paulson JC, Colley KJ: Glycosyltransferases. Structure, localization, and control of cell type-specific glycosylation. J Biol Chem 1989, 264:17615-17618.
33. Yamamoto F, Marken J, Tsuji T, White T, Clausen H, Hakomori S: Characterization and recombination DNA complementary to human UDP-GalNAc:Fuc-alpha1-2Gal alpha1-3GalNAc beta1-3GalNAc beta1-4N-acetylgalactosamine (A antigen) and political difference in the ABO blood group system. Vox Sang 1995, 69:242-247.
34. Gassner C, Schmarda A, Nussbaumer W, Schonitzer D: Allele specific primer PCR across exon 6 resolves potential genotyping errors caused by recombiant hybrid alleles at the ABO locus [abstract]. Transfusion 1998, 38(10S):35.
35. Yamamoto F, Hakomori S: Sugar-nucleotide donor specificity of histo-blood group A and B transfersases is based on amino substitution. J Biochem 1990, 108:1925-1926.
36. Olsson ML, Hansson C, Avent ND, Akesson IE, Green CA, Daniels GL: A clinically applicable method for determining the three major alleles at the Duffy (FY) blood group locus using polymerase chain reaction with allele-specific primers. Transfusion 1998, 38:168-173.
contribute to ABO gene diversity causing various phenotypes. 

38. Ogasawara K, Bannai M, Saitou N, Yabe R, Nakata K, Takenaka M et al.: Extensive polymorphism of ABO blood group gene: three major lineages of the alleles for the common ABO phenotypes. Hum Genet 1996, 97:777-783.

39. Bugert P, Rutten L, Goerg S, Kluter H: Characterization of a novel O1 variant allele at the ABO blood group locus. Tissue Antigens 2001, 58:422-424.